-+ 0.00%
-+ 0.00%
-+ 0.00%
Citi raised CSPC Group's profit forecast and target price, saying that its third-quarter results exceeded expectations, thanks to increased licensing revenue and core business recovery. Analyst John Yung and others said in the report that in view of the better-than-expected growth rate of drug sales, the 2026 revenue and net profit forecasts for the 2026 fiscal year were raised by 2% and 3%, respectively. More than 10 new products/new indications are expected to be approved for launch next year, providing solid support for management's expectations for positive overall growth. The target price was raised from HK$14.6 to HK$15 and the “Buy” rating was maintained.
Share
Listen to the news
Citi raised CSPC Group's profit forecast and target price, saying that its third-quarter results exceeded expectations, thanks to increased licensing revenue and core business recovery. Analyst John Yung and others said in the report that in view of the better-than-expected growth rate of drug sales, the 2026 revenue and net profit forecasts for the 2026 fiscal year were raised by 2% and 3%, respectively. More than 10 new products/new indications are expected to be approved for launch next year, providing solid support for management's expectations for positive overall growth. The target price was raised from HK$14.6 to HK$15 and the “Buy” rating was maintained.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending